ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...
Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...
Seaport names Lauren White as CFO. Ms. White most recently served as CFO at ImmunoGen prior to its acquisition by AbbVie for ...
An influx of late-phase programs has prompted Genmab to reassess its bets. | An influx of late-phase programs has prompted Genmab to reassess its bets. The biotech is axing three early-stage clinical ...
CHICAGO — A real-world study of the ocular side effects of the gynecological cancer treatment mirvetuximab (Elahere) has found more than two of three women taking the drug experienced some type ...
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a ...
Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. Receive News & Ratings for AbbVie Daily - Enter your ...
It’s worth noting that BMS’ decision to exit the deal comes shortly after AbbVie secured full FDA approval for its FRα-directed ADC candidate – Elahere (mirvetuximab soravtansine ...
Barchart on MSN4d
Are Wall Street Analysts Bullish on AbbVie Stock?With a market cap of $356.2 billion, North Chicago, Illinois-based AbbVie Inc. (ABBV) operates in the pharmaceutical sector.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback